Sage Therapeutics’ USPTO Appeal Ends in Voluntary Dismissal at Federal Circuit
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | In re: Sage Therapeutics, Inc. |
| Case Number | 24-1283 (Fed. Cir.) |
| Court | Federal Circuit |
| Duration | Dec 2023 – Apr 2025 1 year 4 months |
| Outcome | Voluntary Dismissal – No Merits Ruling |
| Patent at Issue | |
| Subject Matter | Neuroactive Steroids, Compositions, and Uses Thereof |
Case Overview
The Parties
⚖️ Appellant
Biopharmaceutical company focused on central nervous system disorders, developing neuroactive steroids like ZULRESSO and ZURZUVAE. Patent protection for neuroactive steroids is existential to its competitive position.
🛡️ Respondent
Named in his official capacity as Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the USPTO—the standard governmental defendant in patent prosecution appeals.
Patent at Issue
This appeal centered on U.S. Patent Application No. 15/314,565 (published as US20180179247A1), covering fundamental neuroactive steroid compounds and their therapeutic compositions:
- • US20180179247A1 — Neuroactive steroids, compositions, and uses thereof relevant to CNS drug development.
Developing similar neuroactive steroid products?
Check if your technology might be impacted by related patents or applications.
The Verdict & Legal Analysis
Outcome
The Federal Circuit ordered dismissal pursuant to **Federal Rule of Appellate Procedure 42(b)**, which governs voluntary dismissals by stipulation of the parties. The court’s order specified the proceeding is dismissed and **each side bears its own costs**. No damages were at issue, as this was a prosecution appeal, not an infringement action. No injunctive relief was applicable.
Key Legal Issues
The appeal centered on the patentability of neuroactive steroids under U.S. Patent Application No. 15/314,565. The underlying dispute, classified as an invalidity/cancellation action, suggests the USPTO raised substantive objections, most likely obviousness under 35 U.S.C. § 103 or written description/enablement issues under § 112. The voluntary dismissal prevents public disclosure of which specific grounds were at issue or how the Federal Circuit panel might have ruled.
Drafting pharmaceutical claims?
Learn from complex chemistry cases. Use AI to draft stronger claims that can withstand examination.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis & Strategic Implications
This case highlights critical IP strategy considerations in pharmaceutical R&D. Choose your next step:
📋 Understand This Case’s Impact
Analyze the strategic implications of voluntary dismissals in pharma patent appeals.
- Learn from USPTO appeal dismissal patterns
- See how companies manage complex patent portfolios
- Understand the role of Rule 42(b) in IP strategy
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
Strategic Ambiguity
Dismissal leaves IP status unresolved
1 Patent Application
US15/314,565 at issue
Prosecution Flexibility
Allows continued examination or amendments
✅ Key Takeaways
For Patent Attorneys
Voluntary Rule 42(b) dismissals at the Federal Circuit create no precedent but may signal underlying prosecution developments worth monitoring.
Search related case law →Evaluate whether continued prosecution through amendment can achieve commercial claim scope more efficiently than litigation.
Explore prosecution strategies →For R&D Teams
FTO clearance for neuroactive steroid compositions requires ongoing monitoring of continuation and divisional applications.
Start FTO analysis for my product →Diversify prosecution strategy: no single patent application should represent the sole IP barrier protecting a therapeutic platform.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.